Tedalinab (GRC-10693) 是一种有效的、具有口服活性的、选择性大麻素受体 2 (CB2) 激动剂。Tedalinab 对 CB2 的选择性大 CB1 的 4700 多倍。Tedalinab 具有用于神经性疼痛和骨关节炎的潜力。
| 产品描述 | Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment[1]. [1]. Glenmark's molecule for neuropathic pain, osteoarthritis - GRC 10693, successfully completes Phase I trials. |
m.cnreagent.com
